Protein biomarker discovery has inherent challenges linked to the validation of the analytical method used or to the impact of biological matrices. Matrix influences must be mastered to guarantee the reliability of the identified biomarkers to monitor human diseases. In this study, multiplexed mass spectrometry assays in selected reaction monitoring (SRM) mode have been developed to measure 107 inflammatory putative proteins in matched serum and plasma from 36 ICU trauma patients. The assays' validation directly in clinical samples was shown to be valuable to manage intersample variability. Using the validation process developed here, assays were validated for 58 biomarkers in serum, 57 in plasma, and 55 in both matrices. Correlation analyses demonstrated that the quantitation using SRM of most of the validated biomarkers (45/55) was impacted by the biological matrix and that the matrix impact was biomarker-dependent. Among the 45 impacted biomarkers, 23 were nevertheless correlated between serum and plasma, whereas the quantitation was shown to be equivalent in both for the 10 last proteins. Matrix selection using SRM is therefore suggested to be suitable prior to clinical evaluation of biomarkers in a large cohort of patients.
■ INTRODUCTION
Protein biomarker discovery and validation is a challenge to improve the diagnosis, the prediction, and the monitoring of frequently fatal human diseases. Highly specific and sensitive biomarkers are sought to improve patient care, for example, in the field of sepsis, 1 as they could allow the implementation of targeted therapies previously administered and consequently lower the mortality and morbidity rates, reduce hospital stay, and generally lower patient management cost. 2 Since the 1950s, rapid advances in the mass spectrometry (MS) field have enabled the screening of numerous candidate biomarkers in several clinical contexts. Selected reaction monitoring (SRM) is a tandem mass spectrometry (MS/MS) technique that allows rapid, multiplex, sensitive, and specific analyte quantitation in highly complex sample matrices. 3 Targeted mass spectrometry in SRM mode is based on quantitation of proteotypic peptides (PTPs) as surrogates for the corresponding complete proteins. 4 The assay reproducibility is generally quite good when stable isotope-labeled standards are included in the work flow. This method has been used for decades for the quantitation of low molecular mass analytes (<1000 Da) in pharmaceutical, clinical, and environmental applications. 5 Combined with liquid chromatography (LC) and electrospray ionization (ESI), SRM provides the sensitivity required for detection and quantitation of biological molecules such as peptides in complex biological matrices (e.g., plasma, serum), without depletion of high abundance proteins. 6−8 The ability of multiplexed SRM assays to simultaneously quantify hundreds of proteins in a single experiment enables protein expression profiling of large clinical sample sets in a manner similar to DNA microarray expression profiling in molecular biology. In contrast with ELISA-based assays, which are considered today as the "gold standard" for protein quantitation in clinical samples, SRM-based assays are not supported by an antigen/antibody reaction, but by a physical reaction, limiting affinity and specificity issues. As recently described, 9−11 there is an increasing number of commercially available kits for almost every analyte, but the quality of these assays is sometimes demonstrating a poor antibody specificity, low precision, and high risk of cross reactivity. SRM promises to be an alternative to avoid these types of issues.
However, the use of complex biological matrices may lead to a protein-dependent decrease in the SRM assay specificity and sensitivity. Both plasma and serum are derived from whole blood, leading to different biochemical processes that may impact the concentration of several proteins and metabolites. 12 Several correlation studies have explored the differences between plasma and serum using molecular biology 13 or ELISA technology. 14 In the proteomics field, there is still a debate in the scientific community regarding the impact of the matrix on the titration of circulating biomarkers using SRM. 15−17 The choice of the biological matrix should be included during the validation step of SRM assays. This step is crucial to ensure the robustness and the ability to perform the biomarker quantitation in a large series of clinical samples. The assay validation is usually done using spiked biological matrices with synthetic peptides or recombinant proteins, allowing the evaluation of the selectivity, reproducibility, linearity, and stability of the targeted peptides. 18 The challenge is to manage matrix effects associated with the endogenous interferences (i.e., interferences of endogenous proteins with the analyte of interest). In MS experiments, isobaric ions (with the same mass) produced during the ionization phase could create a competition for detection of the analyte of interest due to their coelution, 19 especially in very complex matrices. In clinical serum and plasma samples, the interpatient variability due to the different levels of endogenous biomarkers or major proteins such as albumin or immunoglobulins G also leads to a variation in the matrix effect. In nondepleted samples, these proteins could interfere by modifying the retention time of analytes during the LC. The matrix concentration could thus modify the retention times of peptides on an LC column.
In this study, 107 assays have been developed to monitor 107 inflammatory putative biomarkers, using MS in SRM mode. To evaluate the impact of the biological matrix on these biomarkers measurement prior to their clinical evaluation in a large cohort of patients, we analyzed matched serum and plasma samples collected from 36 patients from an intensive care unit (ICU) with severe traumatic brain injury. Traumatic patients are known to have inflammatory disorders associated with the trauma-induced immunosuppression, making them highly susceptible to healthcare-associated infections and sepsis. 20 An internal standard (IS) method (with a labeled isotope) was used to account for matrix effects, which can occur in the ion source of the mass spectrometer detector and also to adjust the technical bias linked with the instrument variability from sample to sample (injections) as well as losses of peptides during sample preparation.
Each developed SRM assay was validated using spiked serum and plasma samples to evaluate analytical specificity, sensitivity, reproducibility, and stability. A subsequent step of validation, directly in clinical samples, was performed to limit the impact of intersample variability, which might decrease the assays specificity and lead to incorrect interpretation of the results. Statistical correlation analyses between serum and plasma were performed on all biomarker assays to determine the optimal matrix for the quantitation of each putative biomarker.
■ EXPERIMENTAL PROCEDURES

Materials
Clinical Samples. Matched serum and plasma samples were obtained from 36 adult patients (>18 years) with severe traumatic brain injury. Considering that patients were sedated and intubated at the time of sampling, a next-of-kin was informed and provided written informed consent. Retrospective consent was obtained from patients when possible. The study protocol (Protocol, Eudract number BRD 10/1-L) allowing the collection of samples was approved by an ethical committee (CPP Ouest II, Angers, France).
After collection, EDTA plasma tubes were shaken gently and thoroughly for 15 min, followed by centrifugation at 2750g for 15 min at 15°C, whereas serum tubes were inverted twice, followed by 45 min resting at room temperature to obtain total coagulation. Collection tubes were obtained from BD (BD Vacutainer, Becton, Dickinson and Company). All removed supernatants were frozen at −80°C until the sample preparation step for proteomics analysis.
Standard Solutions. The IS was a pool of heavy isotopelabeled peptides corresponding to the targeted natural peptides, synthesized with incorporated 15 N and 13 C. Both natural and heavy isotope-labeled peptides were exactly coeluted in the chromatographic separation. The volume of each heavy peptide in the IS pool was adjusted to obtain a SRM signal for each peptide of about 10 5 cps (counts per second).
Six quality control samples (QC) were prepared for each matrix to control the data quality and to validate the SRM assays. A stock solution of natural synthetic peptides was first prepared by adjusting volume of each peptide for an SRM signal of about 10 5 cps. This stock solution was then diluted and spiked in a reference pool of serum or plasma from healthy donors, coming from the Etablissement Francais du Sang (EFS Lyon, France), to obtain six QC samples with intensity of signal from low to high level constituting a dynamic range.
Reagents and Chemicals. Methanol, acetonitrile, and water (LC−MS grade) were obtained from Fischer Scientific (Strasbourg, France), dithiotreitol (DTT), iodoacetamide (IAA), urea, formic acid (FA), and ammonium bicarbonate were purchased from Sigma-Aldrich. Trypsin (sequencing grade modified) was obtained from Sigma. Natural and heavy isotopelabeled peptides were internally synthesized using Fmoc chemistry or outsourced to JPT Peptide Technologies (Berlin, Germany).
Instrumentation and Software. LC−MS analyses were performed on a system consisting of a Nexera LC (Shimadzu) HPLC instrument comprising a binary pump and auto sampler coupled to a QTRAP 5500 MS instrument (AB Sciex, Foster City, CA). Instrument control, data acquisition, and processing were performed using the associated Analyst 1.5.2 software. (Table S1A ). Targeted biomarkers were hostresponse biomarkers implicated in the inflammatory process further to an acute stress like surgery, traumatism, or burn. They belong to several families of proteins such as acute phase proteins (e.g., Protein C), alarmins (e.g., Hsp60 or S100A9), cytokines (e.g., TGF-beta-1), proteins implicated in organ dysfunction (e.g., NGAL), apoptosis (e.g., PD-L1), or neuroendocrine and metabolic alterations (e.g., ApoB-100).
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Selection of Peptides. The prediction of trypsic digests was performed with Skyline software 21 using the UniProt accession number for each targeted protein. Only the peptides with a size comprised between 5 and 20 amino acids and without predictable missed-cleavage sites (i.e., undigested sites 22 ) were selected. Peptides with methionine or tryptophan residues were avoided due to their sensitivity to oxidation. On the contrary, peptides with a proline residue in their sequence were promoted because of their ease of fragmentation. One to three PTPs 23 were selected in silico for each protein of the list using Peptide Atlas and GPM databases. 24−26 The selection was restricted to peptides already documented as being more frequently detected in blood by MS technology, providing the strongest specific signal and uniquely identifying the targeted protein ( Figure 1 ).
Sample Preparation. A specific preparation of samples was used to reduce the matrix complexity limiting the matrix effect linked with the coelution of contaminants and analytes of interest. Because the total number of transitions per SRM method is limited (around 120), this preparation also allowed the multiplexing analysis of a large number of peptides from the primary sample distributed after fractionation in several fractions.
Because of technical constraints, sample preparation was accomplished in batches, except for samples used in the validation step. Each experimental batch included nine clinical samples and one QC sample (QC3), which were processed the same day for the sample preparation (digestion and fractionation) and LC−MS analysis. 1. Enzymatic Digestion. 200 μL of QC samples or clinical samples (serum and plasma) spiked with constant amount of heavy isotope-labeled peptides (IS) were denatured by 6 M urea, 5 mM ammonium bicarbonate, pH 8, and 15 mM DTT at 60°C for 40 min. Samples were then alkylated with 35 mM IAA at room temperature in the dark for 40 min. Urea concentration was diluted 8-fold with 50 mM ammonium bicarbonate buffer, pH 8, prior to 4 h digestion at 37°C with 200 μg of trypsin. 2. Mixed Cation Exchange (MCX) and Mixed Anion Exchange (MAX) Peptide Fractionation. This step based on each peptide isoelectric point is essential to simplify the complexity of the matrix and so reduce the matrix effect due to the coelution of the contaminants with the analyte of interest. It also allows us to desalt and to concentrate the samples. Peptide fractionation is based on two mechanisms of retention: hydrophobicity and anionic or cationic retention properties of peptides. Prior to fractionation, digested samples were treated by high frequency ultrasound for 15 min and centrifuged 30 min at 15 000g. The supernatants were acidified with 1 mL of water/2% FA (v/v), pH 3, prior fractionation using a solid-phase extraction (SPE) on MCX cartridges or made basic with 1 mL of water/10% ammonium (v/v), pH 12, prior to MAX fractionation.
The MCX and MAX cartridges (60 mg, 3 cm 3 ) were obtained from Waters (Milford, MA), and the fractionation Figure 1 . Workflow of SRM-based proteomic assays: First, one to three peptides are selected for one targeted protein to improve and enhance the robustness of the analysis of each protein. Then, for each proteotypic peptide the three fragment ions that provide specific and optimal signal intensity to define transitions (m/z values for precursor and fragment ion pairs) were selected. An additional step consisted of an LC−MS experiment to determine retention times of the targeted peptides in each matrix. Finally, validation steps were performed with QC or clinical samples to select peptides with the best analytical performances in order to build the final SRM assay. steps (cartridge-conditioned, sample loading, elution of fractions containing the peptides of interest) were automatized on the RapidTrace SPE Workstation (Biotage, Uppsala, Sweden) using a specific method for each type of cartridge ( Table 1 ). The six eluted fractions per primary sample were partially dried in a nitrogen flow using a TurboVap System (Biotage), and the final volume was adjusted to 250 μL per fraction using water containing 0.5% FA. After 30 min of centrifugation at 15 000g, an aliquot of 100 μL was analyzed by LC-SRM mass spectrometry.
Liquid Chromatography−Mass Spectrometry Conditions. The LC separation was carried out on a C18 reversedphase column 2.1 × 150 mm, 3.6 μ (Aeris Peptide, Phenomenex). Elution was performed in 41 min at a flow rate of 250 μL/min with water containing 0.1% FA (v/v) as solvent A and methanol containing 0.1% FA (v/v) as solvent B. An isocratic step at 5% solvent B during 2 min was followed by a 37 min linear gradient from 5 to 60% solvent B and then a 2 min isocratic step at 5% solvent B. The oven temperature is 60°C
. MS analysis was carried out in positive mode using an ion spray voltage of 5500 V in a QTRAP 5500 MS instrument (AB Sciex). The mass spectrometer was initially tuned and calibrated using polypropylene glycol as standard (AB Sciex) according to the manufacturer's instructions. Q1 and Q3 quadrupole resolution was adjusted to 0.7 ± 0.1 atomic mass unit, full width at half-maximum, referred to as unit resolution. The nebulizer (air) and the curtain gas flows (nitrogen) were set at 40 and 50 psi, respectively. The Turbo V ion source was operated at 550°C with the auxiliary gas flow (nitrogen) set at 40 psi.
SRM Transitions Optimization. The SRM acquisition methods were constructed using optimized transitions (m/z value combination of the first and third quadrupole) with peptide-specific tuned declustering potential (DP), enhanced potential (EP), collision energy (CE), and collision cell exit potential (CXP) voltages. These parameters were obtained after infusion of natural or heavy synthetics peptides diluted in 50% acetonitrile/0.1% FA. For each peptide, three transitions (m/z values for precursor and fragments pairs) were selected with the optimal signal intensity. A 4 min detection time window ("RT window") around the peptide retention time experimentally observed in serum or plasma sample, spiked with synthetic peptides, was used for acquisitions in Schedule mode for SRM experiments with a target scan time of 1.15s.
Validation. First the robustness of the titration method was assessed by validating the absence of interfering signal at the retention time of the analyte. Interference determinations are necessary due to the complexity of the biological sample. These selectivity experiments were performed with water samples spiked with the pool of IS. The absence of interfering signal from the IS with analyte transitions was verified. A validation step including precision, linearity, and stability studies has been performed on QC samples, added with IS to assess the interday reproducibility, the specificity, and the sensitivity of each assay for all monitored biomarkers. The experimental protocol for validation is shown in Table 2 .
The linearity study was performed using the six QC samples (QC0 to QC5) with three repetitions from Day 0 to Day 2. For the precision study, the assays were performed with QC1, QC3, and QC5 samples (two preparations of each sample each day, five different days), whereas QC1 and QC3 samples were used for the stability study of samples at 20°C "on rack" between 0 to 96 h (each 24 h). The QC3 sample (medium level of signal) was also used as an indicator of the interbatch reproducibility. Any significant variation observed on QC3 profiles is designed to alert the operator regarding a possible deviation of the a Robustness of the developed titration method was assessed for each biomarker using QC0 to QC5 with two batches of sample preparation and four time points for injection (D0 to D4). Limit of detection (LOD) has been determined in the linearity study; lower limit of quantitation (LLOQ) has been determined in the precision study, and the stability of extracted samples in the holder at 20°C for 96 h has been determined in the stability study.
Article experimental process. A second validation step (feasibility study) was done directly in serum and plasma from four patients to optimize the selection of "RT window of detection" for each peptide during SRM analysis.
MS Data Analysis
Scheduled SRM data processing was performed using Multiquant 2.1 software (AB Sciex) using the integration algorithm Signal Finder. The software allows us to extract a chromatogram corresponding to each peptide with specific parameters and to calculate area under the curve for both analyte and IS SRM peaks. A QC of the integrated data was performed using the following criteria: (a) the RT variability of all transitions for a given peptide had to be inferior to 0.1 min, (b) the IS intensity (peak height of IS) had to exceed a minimum intensity threshold of 500, (c) the analyte intensity (peak height of analyte) had to exceed a minimum intensity threshold of 500, and (d) the area under peak ratios for transitions of the same peptide had to be close (coefficient of variation (CV) < 20%).
Statistical Analyses
R session version 3.0.0 (2013-04-03, x86_64-unknown-linuxgnu) was used for statistical analysis.
The results were presented as the analyte (AN)/internal standard (IS) ratio or as the AN/IS ratio transformed with log 2. AN/IS ratio was defined as the ratio of the light peptide peak area compared with the heavy peptide peak area. All of the ratios are shown in Tables S5−S8. Correlation analyses were performed using Spearman correlation coefficient (cor), which measures the strength of a relation between two variables. Correlations were calculated for AN/IS ratios between transitions and between peptides of each protein for the validation step. Spearman correlation coefficients were computed for AN/IS ratios between serum and plasma for each measured protein at transition, peptide, and protein levels to assess the correlation between matrices. The correlation between ELISA and SRM technology was performed using GraphPad Prism version 5 software.
The analyses were complemented with a Bland Altman plot, 27 method of data plotting, to assess the agreement between assays in serum and plasma and to identify a possible relationship between the differences and the magnitude of measurements in both matrices. We also looked for any systematic bias. The distribution of AN/IS ratios between both matrices was studied with a paired-Wilcoxon signed-rank test. This test is a nonparametric statistical hypothesis test used when comparing two related samples (matched samples) to assess whether their population mean ranks differ (i.e., it is a paired difference test). 28 A significant test means that the distribution of AN/IS ratios is not identical between both matrices. table (A) : First, the precision study (C) consists of the titration in both matrices of three samples spiked with all synthetic peptides at different ranges of levels (QC1, QC3, QC5). Then, the reproducibility between days was evaluated on QC3 sample. The step of missing data checking allowed us to eliminate the transitions for which the signal was not detected in >25% of samples. An example of a correlation plot (Spearman coefficient) for all transitions for the protein C4bp is represented in graph D: In this case the protein assay was performed after compilation of data for six transitions representing two peptides.
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Article ■ RESULTS
Validation of the Assays
Referent pools of serum or plasma samples from healthy donors spiked with natural peptides at several concentrations (QC samples) were used to validate linearity, sensitivity, reproducibility and stability of sample preparation in this study. The precision of the method was established by calculating for each sample the interday CV of areas under peak ratios for all analyzed transitions. The technical variability was higher in serum than in plasma, as illustrated in Figure 2C for the fraction F5−8, but most of the monitored transitions showed a CV below 20% (fixed criteria for acceptance, Figure 2A ), depending on the analyzed fractions. It was impossible to obtain the linearity and sensitivity for some proteins due to the unavailability of blank matrices (without any present endogenous analyte). The basal concentration of endogenous peptides in the pool of samples used was non-negligible, leading to the inability to observe the limit of detection and to determine a limit of quantitation (LoQ) for these proteins. Dynamic ranges with recombinant proteins in depleted serum or plasma could have allowed the determination of LoQ; 29 however, as the number of biomarkers in this study was very high (107 targeted proteins), this technique was not used for cost reasons.
The stability analysis was performed on the validated transitions with respect to (a) the precision, with the following acceptance criteria: CV < 20% for QC1 and QC3, and (b) values of ratios for each transition, with the following acceptance criteria: H0−2SD < ratio value < H0+2SD (SD = standard deviation of the precision study). The stability analysis demonstrated that peptides with correlated transitions were globally stable at 20°C between H0 and H96. According to these results, samples were injected and data were generated during the first 48 h after sample preparation.
Scheduled SRM methods developed required retention time window adjustments due to the high complexity of QC samples (spiked pools of sera or plasma). These have been accomplished using serum and plasma samples from four independent patients. The retention time for each peptide has thus been optimized. On the basis of these results, the SRM method allowed the monitoring of 285 validated peptides representing the 107 targeted proteins. Table S2 shows detailed SRM method parameters. Among the 107 developed assays (corresponding to the 107 selected proteins), 75 proteins of interest were kept for analysis. Most of the proteins eliminated were not "technically" detected (no signal for the IS). This was the case for four proteins in both serum and plasma: HLE, HMG-1, TREM-1, and ALP. Some others did not present correlated transitions in clinical samples, for example, RAGE or Ferritin H subunit.
Subsequently, quality controls (QC3) were included in all experimental batches of nine samples to control the reproducibility during the analysis of clinical samples. Transitions for which the CV in the QC3 sample was <20% were selected. Plasma and serum samples are biological matrices with high amounts of proteins. To take into account the huge variability in matrix effect associated with the different amounts of major proteins from sample to sample, an approach based on the correlation of transitions from all of the peptides representing a protein has been developed. This approach allowed the selection of the transitions least impacted by the variability of matrix effect between samples, leading to the selection of peptides with a lower technical variability to improve the observation of biological variability. The full workflow is represented in Figure 2B , including the fixed Figure 2A . All of the transitions with a low CV, with a good reproducibility in QC samples between days, with <25% of missing data, and with a Spearman correlation coefficient superior to 0.9 were thus selected and compiled in one data value for the analysis at the protein level using the median of ratios AN on IS (analyte's area under curve compared with IS's area under curve).
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As an example, for the protein C4bp ( Figure 2D ), monitored with nine transitions, among them six (representing two peptides) were intra-and inter-peptide-correlated (green frame), whereas the three other transitions from the third peptide were intra-peptide-correlated but were not correlated with all of the other transitions (black rectangles). The transitions of this peptide have therefore not been selected at the protein level.
On the basis of this workflow and associated criteria ( Figure  2A) , specific SRM methods have been developed and validated, dedicated to each type of sample matrix: serum and plasma. Thus, 59 assays were validated in plasma and 58 assays were validated in serum. The developed methods gave a relative proportion between the AN and the IS (ratio of the light peptide peak area compared with the heavy peptide peak area).
Finally, the validated multiplexed methods allowed the reliable quantitation (analytically robust) of 58 inflammatory proteins in serum, represented by 95 peptides, in a single experiment using 200 μL of sample, and in a second experiment 59 inflammatory proteins in plasma were monitored, represented by 101 peptides. Details of all of the proteins monitored with the developed methods, including the selected peptides (with amino acid sequence) and transitions for each protein, as well as the matrix in which the assay was validated, are available in Table S1B .
A correlation study between the developed MS assay and an ELISA assay was performed on several biomarkers with 29 clinical samples to assess the method developed and showed a good correlation between both methods, for example, for ApoA-IV ( Figure 3 ). MS ratios (data summed for the three PTPs representing this protein) and ELISA data were significantly correlated with a Spearman correlation coefficient equal to 0.93.
On the basis of "the matrix in which the assay was validated" criterion, four groups of proteins were identified:
• 55 proteins were measurable in both matrices, as most apolipoproteins, PCSK9 (proprotein convertase subtilisin, kexin type 9) or vWF (von Willebrand factor) • 3 proteins were measurable in plasma only: S100A8, VCAM-1 (vascular cell adhesion protein 1), and Prx-IV (peroxiredoxin-4) • 2 proteins were measurable in serum only: TLT-1 (tremlike transcript 1 protein) and PTX3 (pentraxin-related protein PTX3). • 14 proteins were measurable neither in plasma nor in serum (titration method not validated); examples: heat shock 70 kDa protein 2 or MCSF (macrophage colony stimulating factor 1). Figure 4 represents the data by matrix and by family of proteins. No link between the family of proteins and the measurability in serum or plasma matrix was established. Nevertheless, the three proteins representing the family of . Protein assays validated in serum or plasma matrices: Classification by protein family (color coded): among the analysis of 75 proteins of interest, the titration was validated for 58 biomarkers in the serum matrix, and for 59 biomarkers in the plasma matrix. In the case of Cathepsin G (CG)* r the two different peptides were validated in separate matrices, and thus this biomarker was not kept for the correlation study. The correlation analysis was performed for the 55 proteins in common in the two matrices (central circle). In fact, 14 proteins were not measurable in either of the two matrices.
Article "vasoactive molecules" (adrenomedullin, vasopressin-neurophysin 2-copeptin, and elastin) could not be validated in either matrix, likely due to the low concentration of these proteins (picomol/mL) in a normal context. 30, 31 
Protein-Dependent Correlation between Serum and Plasma
The expression level of the 55 proteins validated in both matrices, representing 88 peptides and 326 transitions, was measured in a total of 36 ICU trauma patients using SRM assays developed. Spearman correlation coefficients were computed between serum and plasma per transition, per peptide and per protein. Only the transitions showing detectable signal (intensity level higher than 500 cps) for at least 75% of patients (27 patients) were kept for the statistical analysis. In the case in which several peptides from different fractions were validated for one biomarker, all of the selected transitions data were compiled using the median of ratio "AN/ IS", regardless of the elution fraction used, first for the interpretation at the peptide level and subsequently at the protein level.
At the transition level, 155 transitions (47.5%) were correlated between serum and plasma matrices, of which 91 had a Spearman coefficient between 0.8 and 0.9 and 64 were superior to 0.9. At the peptide level, after compilation of validated transitions using median of ratios, 56 peptides (64%) had a Spearman coefficient higher than 0.8, of which 26 were between 0.8 and 0.9 and 30 were superior to 0.9. Spearman correlation coefficients calculated at transition and peptide levels are available in Tables S3 and S4, respectively. At the protein level, after compilation of validated peptides using median of ratios, 33 proteins (60%) correlated (cor >0.8) between serum and plasma matrices, among them 13 with a Spearman coefficient between 0.8 and 0.9 and 20 with a Spearman coefficient superior to 0.9, which are listed in Table  3 . Figure 5 represents the correlation graphs between serum and plasma samples for ApoB-100 at the transition level (A), the peptide level (B), and the protein level (C). Among the nine monitored transitions, six correlated between serum and plasma, whereas three did not, as illustrated on the graphs in Figure 5A . These three noncorrelated transitions of a unique peptide PEP-1 (ATFQTPDFIVPLTDLR) were validated in serum and in plasma separately, whereas they were not correlated at the peptide level (cor = 0.62). This peptide was not selected for the analysis at the protein level. Only the values for the six validated transitions for PEP-2 (IEGNLIFDPNNY-LPK) and PEP-3 (GFEPTLEALFGK) were compiled to obtain the median of ratios for the protein ApoB-100. For this protein, the MS titration correlated between serum and plasma with a Spearman coefficient value of 0.98.
Because the Spearman correlation coefficient measures the strength of a relation between two variables, not the agreement between them, a Bland-Altman analysis was subsequently assessed to identify the potential bias between both matrices. Different profiles were observed. Figure 6 represents the Bland-Altman plots between plasma and serum and the paired plot graphs representing the distribution of ratios AN/IS by matrix associated with patients. Proteins RBP, AGP1, and MPO show typical profiles. In fact, for MPO, the profile corresponds to the case of a proportional bias, meaning that the difference between methods tends to get larger as the average increases, as illustrated on the paired plot graph. For AGP1, the profile corresponds to the case of a systematic bias meaning that the PSP-2 serpin A1 RBP TGF-beta-1 SAA TIMP-1 YKL-40 transferrin vWF total: 22 proteins total: 13 proteins total: 20 proteins a 22 of the 55 analyzed proteins were not correlated in the two matrices (A), whereas 33 were, representing 60% of the measured biomarkers. 13 had a correlation coefficient (cor) between 0.8 and 0.9 (B) and 20 had a correlation coefficient superior to 0.9 (C).
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Article ratios are systematically higher in serum, as shown on the paired plot. Both methods may be considered to be equivalent for RBP, for which there is no bias. As a general trend, paired plot graphs show that ratios were higher in serum than in plasma. This observation was confirmed with a paired Wilcoxon signed rank test. In fact, the adjusted p value with an FDR correction 32 was significant for most of the correlated proteins (70%), meaning that the distribution was not identical between serum and plasma, showing the impact of the biological matrix on their titration. Table 4 shows the results of the Wilcoxon test for the 33 correlated proteins between serum and plasma (cor > 0.8). For 10 of them, the test was not significant (p value > 0.05), meaning that the distribution of AN/IS ratios was not different between serum and plasma; they were not impacted by the biological matrix. These 10 proteins are C4a-anaphylatoxin, PCSK9, LBP, ApoC-III, ApoB-100, ApoL-1, β2-microglobulin, osteopontin, MMP-2, and RBP. For these proteins, we could choose without preference one or the other matrix.
These results, summarized in the Figure 7 , indicate that the biological matrix can impact the titration of most of biomarkers, and this impact has to be assessed when possible before selecting one matrix for a study, depending on the biomarker.
■ DISCUSSION
In this study, a reliable SRM multiplex assay was optimized, allowing the measuring, with analytical robustness, of a large number of proteins in a low sample volume (200 μL). In agreement with the Food and Drug Administration guidelines on bioanalytical method validation (FDA, 2001), 33 a structured validation process was undertaken, including validation of the robustness and limitation of variability among clinical samples. According to the acceptance criteria defined in Figure 2A , the results demonstrated a good reproducibility of protein measurements in both plasma and serum (CV% < 20%, Figure  2C ), as previously described; 34, 35 however, a better reproducibility in plasma compared with serum samples was shown with the current assay. In contrast, serum analysis achieved a better sensitivity with higher relative concentrations of most of the monitored proteins. These data are similar to those observed in a previous study describing the impact of the matrix on the titration of 163 metabolites in plasma and serum samples. 12 Nevertheless, several constraints were faced during the validation of the SRM methods developed and the assessment of their robustness. The lack of blank matrix to make the analytical adjustments of the methods incited us to set up QC samples based on a pool of serum or plasma samples from healthy volunteers spiked with synthetic natural peptides representing the analyte of interest. Therefore, the QC "standard" was more complex than a real clinical sample collected from a unique patient, leading to the nonvalidation of several peptide/protein assays, in particular for proteins with low concentrations, because of the complexity of the artificial matrix.
In comparison with the study of Kennedy et al., 36 the analytical validation of the SRM assay described here was more 
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Article stringent, leading to the rejection of a higher number of proteins. Kennedy et al. considered an assay as successful if it was precise (CV% < 20% at the lowest concentration point in the linear range of the assay) and specific (detection of one transition of the light and two transitions of the heavy peptide and perfect coelution of heavy and light peptides). In the current study the assays met more criteria (precision, specificity, missing data, and correlation between transitions intra-and interpeptide) to be considered successful ( Figure  2A ). The described validation approach allows the selection of the best peptides for each protein to reduce the technical variability to observe more easily the biological variability. The study of Worboys et al. 37 supports this approach. They have shown the importance of identifying peptides with good quantotypic (not only proteotypic) properties to accurately represent the level of the protein in biological samples.
Despite the dedicated sample preparation and the LC−MS method developed that aimed at reducing and compensating matrix effects such as ion competition, signal suppression, or interfering compounds, the current study demonstrates that in a general trend the titration of a biomarker was impacted by the biological matrix (e.g., plasma or serum). Indeed, only 10 markers were not affected by the matrix out of the 55 validated in both matrices (18%). For 42% of the validated biomarkers in both matrices (n = 23 of 55), the titration was well correlated between serum and plasma, but the relative concentration was not equivalent (significantly paired Wilcoxon p value). For all of these biomarkers the relative concentration was higher in serum than in plasma, except for the Prothrombin protein, that could be explained by its implication in the coagulation process. 38 The two other studied proteins belonging to the same family (coagulation proteins) were not impacted by the sample matrix, so this study did not highlight a visible link between the family of proteins and the ability to monitor them in one or the other matrix. Finally, 22 out of the 55 validated proteins in both matrices (40%), were not correlated in serum and plasma, showing that the measurement of proteins may be impacted by the preparation of the primary sample tube of serum and plasma. As already described by the group of Trufelli, who reviewed the different types of matrix effects in LC−MS, 39 preanalytical step may be responsible for blood components release or protein complex formations that may impact the concentration of proteins. The time taken to prepare blood samples (from the collection tubes to the analysis) is also known to impact the concentration of most proteins. 18 Retention times were also shown to be impacted by the biological matrix, which can generate a systematic shift in serum or in plasma, as illustrated in Figure S1 for APO-A4, in opposition to APO-L1, which was less impacted. (alpha-1 acid glycoprotein 1), and myeloperoxidase (MPO). For these three proteins there was no missing data and the plots represented the 36 patients analyzed. For RBP protein the assay was highly correlated between the two matrices (cor = 0.92), there was no bias. AGP1 and MPO were not correlated between serum and plasma (cor < 0.8 for both proteins). AGP1 showed a systematic bias on the Bland Altman graph, whereas MPO showed a proportional bias.
On the basis of our overall results, we recommend to evaluate both matrices and to select the best sample type for each biomarker prior to their clinical evaluation. Although our study cannot give universal criteria for the selection of the most appropriate sample type, we recommend to select the one in which the matrix effect least disturbs the measurement of the clinical effect to be studied. According to our results and in the referred clinical context (sepsis), we would recommend to favor the most sensitive matrix to maximize the chances of identifying the intended clinical effect. Applying these criteria to some of the studied proteins, Protein S, C3a, CRP, and Complement Factor I would thus be investigated preferentially in serum, whereas Prothrombin and S100-A9 would thus be preferentially investigated in plasma, although they are measurable in both matrices (Figure S2B,C) . For LBP, Apo-B100, MMP-2, and RBP, we could choose without preference one or the other matrix ( Figure S2A ). Another criterion could be the linearity that could be evaluated by spiking recombinant proteins corresponding to each putative biomarker, according to a range of defined concentrations, in each biological matrix. In function of the expected clinical effect, the most linear biological matrix could be selected. The current study did not evaluate the linearity of each biomarker in serum and in plasma because of the high number of biomarkers to be studied, the nonavailability of all recombinant proteins, and the rarity of the clinical samples (precious).
Despite the dedicated sample preparation and the LC−MS method developed, validated in agreement with the FDA recommendation, our study highlights the existence of matrix effects, especially associated with the biological matrix, serum, or plasma, which can impact the quantitation of most proteins. Although the current study could contribute to the definition of a methodology to evaluate matrix effect, criteria for matrix selection have to be defined case by case, as a function of the biomarker to be studied and as a function of the referred clinical context.
■ CONCLUSIONS
Clinicians rely heavily on diagnostic tests for patient management, especially those with potentially fatal disease such as sepsis. Although host response inflammatory proteins and peptides currently known to be associated with these diseases are numerous (>100), diagnostic monitoring of them is frequently hindered by analytical difficulties to measure accurate concentrations, mainly in the presence of low levels of biomarkers amidst high levels of endogenous proteins. Using serum and plasma from 36 ICU trauma patients, the SRM assays developed, validated, and reported here allow the robust analytical measurement of 58 biomarkers in serum, 59 in plasma, and 55 in both matrices. The study results nevertheless show that the biological matrix can impact the measurement of most of these reported human inflammatory proteins (45 of 55). Only 10 biomarkers can be measured with equivalence in both serum and plasma.
These assays performed using an IS method demonstrate that SRM can be a powerful discriminatory tool to determine the matrix impact on biomarker quantitation in addition to SRM's capacity to quantitate low levels of proteins. 7 a Among the list of proteins (A) that were highly correlated in serum and plasma (cor > 0.8) (B), the titration of 10 proteins was considered to be equivalent between serum and plasma (non significant adjusted p value > 0.05, in bold) (C). For most of the proteins (60%) the distribution was not identical in serum and plasma (significant p value <0.05), although the correlation is good between both matrices. Figure 7 . Summary of correlation study results for the 55 validated proteins in both matrices. Among the 55 validated proteins in both matrices, 33 were correlated between serum and plasma, whereas 22 were not. Ten of the 33 correlated proteins were equivalent between both matrices, whereas 23 were not. In summary, 45 proteins were impacted by the biological matrix (orange framed).
These studies highlight the importance of the analytical validation of SRM assays, especially for quantitative studies. Using validated SRM assays, clinical evaluations of large patient cohorts can thus benefit from the preanalytical selection of the most suitable sample type to ultimately identify clinically relevant diagnostic biomarkers with increased confidence.
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